Alvotech
Dedicated to broadening the availability and accessibility of biosimilars.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | SEK750m | Private Placement non VC |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (45 %) | 126 % | 10 % | 436 % | 33 % | 37 % | 44 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (457 %) | (393 %) | (366 %) | 21 % | 37 % | 43 % | 41 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (276 %) | (619 %) | (603 %) | (47 %) | 6 % | 16 % | 21 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 519 % | 218 % | 231 % | 35 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Alvotech is a biopharmaceutical company that specializes in the development and manufacturing of biosimilars, which are essentially less expensive versions of biologic medicines. These medicines are used in the treatment of a variety of diseases, making Alvotech's work crucial in the healthcare sector. The company's primary goal is to improve lives by making biologic medicines more accessible and affordable.
Alvotech operates in the global pharmaceutical market, serving a wide range of clients, including healthcare providers and patients. The company's business model is vertically integrated, meaning it controls every stage of the process, from cell line development to the final stages of manufacturing. This approach allows Alvotech to maintain control, scale operations, and speed up the production process, thereby enhancing efficiency and cost-effectiveness.
The company generates revenue by selling its high-quality, cost-competitive biosimilars to healthcare providers worldwide. Alvotech also continually evaluates additional pipeline opportunities to expand its selection of biologic medicines, which could potentially lead to increased revenue streams.
Alvotech's recent financial results and business updates indicate positive growth and development, with the company announcing positive top-line results from a pharmacokinetic study for a proposed biosimilar. This suggests that Alvotech is not only maintaining its current operations but also actively pursuing new opportunities for growth and expansion.
In summary, Alvotech is a purpose-driven biopharmaceutical company that aims to improve lives by making biologic medicines more accessible and affordable.
Keywords: Biopharmaceutical, Biosimilars, Healthcare, Vertically Integrated, Cost-effective, Global Market, Pipeline Opportunities, Biologic Medicines, Growth, Expansion.